Overview

To Compare the Ability of DiscoVisc® OVD to Protect the Corneal Endothelium and Maintain Anterior Chamber Space With Healon® and Amvisc® PLUS During Cataract Surgery.

Status:
Completed

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

The objective of the study is to assess how DisCoVisc Ophthalmic Viscosurgical Device (OVD) compares with Healon and Amvisc Plus in the protection of corneal endothelial cells, and the ability to maintain anterior chamber space, in routine cataract surgery.

Phase:

Phase 4

Details

Lead Sponsor:

Alcon Research

Treatments:

Hyaluronic Acid